Current Rheumatology Reports

, 10:74

The enigmas of the lupus anticoagulant: Mechanisms, diagnosis, and management

Article
  • 112 Downloads

Abstract

Lupus anticoagulant (LA) is a laboratory abnormality associated with the antiphospholipid syndrome. It is a paradoxical phenomenon in which one or more in vitro diagnostic clotting tests are prolonged and thus seem due to an anticoagulant, whereas the antiphospholipid syndrome is manifest clinically as inappropriate or excessive thrombosis. LA should be suspected when thrombosis, recurrent fetal loss, or a prolonged phospholipid (PL)-dependent clotting test is present without other identifiable causes. Despite the heterogeneity of LA antibodies, a consensus has evolved to identify the LA. Four conditions must be met for this laboratory diagnosis: 1) prolongation of a PL-based clotting test, 2) confirmation of an inhibitor-like pattern in the clotting test, 3) confirmation of PL dependence in coagulation tests, and 4) exclusion of a specific factor inhibitor. Even with an extensive armamentarium for LA diagnosis and treatment, it is still a formidable task.

References and Recommended Reading

  1. 1.
    McNeil HP, Chesterman CN, Krilis S: Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991, 49:193–280.PubMedGoogle Scholar
  2. 2.
    Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006, 4:295–306.PubMedCrossRefGoogle Scholar
  3. 3.
    Galli M: Antiphospholipid syndrome: association between laboratory tests and clinical practice. Pathophysiol Haemostas Thromb 2003, 33:249–258.CrossRefGoogle Scholar
  4. 4.
    Feinstein DI, Rapaport SI: Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972, 1:75–95PubMedGoogle Scholar
  5. 5.
    Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemostas 1995, 74:1185–1190.Google Scholar
  6. 6.
    de Laat HB, Derksen RH, Urbanus RT, et al.: Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004, 104:3598–3602.PubMedCrossRefGoogle Scholar
  7. 7.
    Sailer T, Vormittag R, Zoghlami C, et al.: The clinical significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. Thromb Res 2007, 120:295–302.PubMedCrossRefGoogle Scholar
  8. 8.
    Gainnakopoulos B, Passam F, Rahgozar S, Krillis SA: Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007, 109:422–430.CrossRefGoogle Scholar
  9. 9.
    de Groot PG, Derksen RH: Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005, 3:1854–1860.PubMedCrossRefGoogle Scholar
  10. 10.
    Griffin JH, Fernadndez JA, Gale AJ, Mosinier LO: Activated protein C. J Thromb Haemostas 2007, 5(Suppl 1):73–80.CrossRefGoogle Scholar
  11. 11.
    Buil A, Soria JM, Souto JC, et al.: Protein C levels are regulated by a quantitative trait locus on chromosome 16: results from the Genetic Analysis of Idiopathic Thrombophilia (GAIT) Project. Arterioscler Thromb Vasc Biool 2004, 24:1321–1325.CrossRefGoogle Scholar
  12. 12.
    Carson CW, Comp PC, Rezaie AR, et al.: Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000, 27:384–390.PubMedGoogle Scholar
  13. 13.
    Safa O, Esmon CT, Esmon NL: Inhibition of APC anticoagulant activity on oxidized phospholipid by antibeta2-glycoprotein I monoclonal antibodies. Blood 2005, 106:1629–1635.PubMedCrossRefGoogle Scholar
  14. 14.
    Forastiero RR, Martinuzzo ME, Lu L, Broze GJ: Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 2003, 1:1764–1770.PubMedCrossRefGoogle Scholar
  15. 15.
    Salemink I, Blezer R, Willems GM, et al.: Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000, 84:653–656.PubMedGoogle Scholar
  16. 16.
    Meroni PL, Del Papa N, Raschi E, et al.: Beta2-glycoprotein I as a ‘cofactor’ for anti-phospholipid reactivity with endothelial cells. Lupus 1998, 7(Suppl 2):S44–S47.PubMedCrossRefGoogle Scholar
  17. 17.
    Lutters BC, Derksen RH, Tekelenburg WL, et al.: Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003, 278:33831–33838.PubMedCrossRefGoogle Scholar
  18. 18.
    Patterson AM, Ford I, Graham A, et al.: The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells. Br J Haematol 2006, 133:323–330.PubMedCrossRefGoogle Scholar
  19. 19.
    Combes V, Simon AC, Grau GE, et al.: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999, 104:93–102.PubMedCrossRefGoogle Scholar
  20. 20.
    Arslan E, Colakolu M, Celik C, et al.: Serum TNF-alpha, IL-6, lupus anticoagulant and anticardiolipin antibody in women with and without a past history of recurrent miscarriage. Archiv Gynocol Obst 2004, 270:227–229.CrossRefGoogle Scholar
  21. 21.
    Dignat-George F, Camoin-Jau L, Sabatier F, et al.: Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004, 91:667–673.PubMedGoogle Scholar
  22. 22.
    Dobado-Berrios PM, Lopez-Pedrera C, Velasco F, Aguirre MA: Torres A. Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemostas 1999, 82:1578–1582.Google Scholar
  23. 23.
    Zhou H, Wolberg AS, Roubey RA: Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004, 104:2353–2358.PubMedCrossRefGoogle Scholar
  24. 24.
    Meroni PL, Raschi E, Testoni C, et al.: Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001, 44:2870–2878.PubMedCrossRefGoogle Scholar
  25. 25.
    Raschi E, Testoni C, Bosisio D, et al.: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 101:3495–3500.PubMedCrossRefGoogle Scholar
  26. 26.
    Robbins DL, Leung S, Miller-Blair DJ, Ziboh V: Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998, 25:51–56.PubMedGoogle Scholar
  27. 27.
    Yap CL, Anderson KE, Hughan SC, et al.: Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). Blood 2002, 99:151–158.PubMedCrossRefGoogle Scholar
  28. 28.
    Cesarman-Maus G, Rios-Luna NP, Deora AB, et al.: Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107:4375–4382.PubMedCrossRefGoogle Scholar
  29. 29.
    Triplett DA: Antiphospholipid antibodies. Clin Adv in Hematol Oncol 2003, 1:726–730.Google Scholar
  30. 30.
    Jacobsen EM, Barna-Cler L, Taylor JM, et al.: The Lupus Ratio test-an interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants-ISLA 5. Thromb Haemost 2000, 83:704–708.PubMedGoogle Scholar
  31. 31.
    Wong RC, Adelstein S, Gillis D, Favaloro EJ: Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. Semin Thromb Hemost 2005, 31:39–48.PubMedCrossRefGoogle Scholar
  32. 32.
    Galli M, Luciani D, Bertolini G, Barbui T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827–1832.PubMedCrossRefGoogle Scholar
  33. 33.
    Sanna G, Bertolaccini ML, Cuadrado MJ, et al.: Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003, 30:985–992.PubMedGoogle Scholar
  34. 34.
    Branch DW: Antiphospholipid antibodies and fetal compromise. Thromb Res 2004, 114:415–418.PubMedCrossRefGoogle Scholar
  35. 35.
    Van Horn JT, Craven C, Ward K, et al.: Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004, 25:642–648.PubMedCrossRefGoogle Scholar
  36. 36.
    Sebire NJ, Fox H, Backos M, et al.: Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 2002, 17:1067–1071.PubMedCrossRefGoogle Scholar
  37. 37.
    Lawrie AS, Mackie IJ, Purdy G, Machin SJ: The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999, 81:758–762.PubMedGoogle Scholar
  38. 38.
    Brancaccio V, Ames PR, Glynn J, et al.: A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Blood Coagul Fibrinolysis 1997, 8:155–160.PubMedCrossRefGoogle Scholar
  39. 39.
    Jacobsen EM, Barna-Cler L, Taylor JM, et al.: The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb Res 2001, 104:275–282.PubMedCrossRefGoogle Scholar
  40. 40.
    Tripodi A, Chantarangkul V, Clerici M, Mannucci PM: Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 2002, 88:583–586.PubMedGoogle Scholar
  41. 41.
    Arnout J: Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001, 86:83–91.PubMedGoogle Scholar
  42. 42.
    Le Querrec A, Arnout J, Arnoux D, et al.: Quantification of lupus anticoagulants in clinical samples using anti-beta2GP1 and anti-prothrombin monoclonal antibodies. Thromb Haemost 2001, 86:584–589.PubMedGoogle Scholar
  43. 43.
    Clauser S, Fischer AM, Darnige L: Quinidine-induced lupus anticoagulant, hypoprothrombinemia, and antiprothrombin antibodies. Am J Hematol 2007, 82:330.PubMedCrossRefGoogle Scholar
  44. 44.
    Greaves M, Cohen H, Machin SJ, Mackie I: Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000, 109:704–715.PubMedCrossRefGoogle Scholar
  45. 45.
    Deitcher SR, Carman TL, Kottke-Marchant K: Simultaneous deep venous thrombosis and acquired factor VIII inhibitor. Clin App Thromb Hemost 2002, 8:375–379.CrossRefGoogle Scholar
  46. 46.
    Pierangeli SS, Chen PP, Gonzalez EB: Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Op Hematol 2006, 13:366–375.Google Scholar
  47. 47.
    Ansell J, Hirsh J, Poller L, et al.: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:204S–233S.PubMedCrossRefGoogle Scholar
  48. 48.
    Rosborough TK, Shepherd MF: Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 2004, 24:838–842.PubMedCrossRefGoogle Scholar
  49. 49.
    Ridker PM, Goldhaber SZ, Danielson E, et al.: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348:1425–1434.PubMedCrossRefGoogle Scholar
  50. 50.
    Finazzi G, Marchioli R, Brancaccio V, et al.: A randomized clinical trial of high-intensity Warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848–853.PubMedCrossRefGoogle Scholar
  51. 51.
    Thom J, Ivey L, Gilmore G, Eikelboom JW: Evaluation of the phospholipid-rich dilute Russell’s viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. Blood Coagul Fibrinolysis 2004, 15:353–357.PubMedCrossRefGoogle Scholar
  52. 52.
    Bates SM, Greer IA, Hirsh J, Ginsberg JS: Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:627S–644S.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Laboratory Services #113Oklahoma City Veterans Administration Medical CenterOklahoma CityUSA

Personalised recommendations